Skip to main content

Table 1 The effect of WAY100635, prazosin or clonidine on the striatal dopamine, DOPAC and HVA

From: Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson’s disease

  Dopamine DOPAC HVA Turnover rate
Vehicle 19.49 ± 0.75** 1.62 ± 0.12** 1.03 ± 0.04** 0.14 ± 0.01
WAY100635 (0.05 mg/kg) 18.22 ± 1.21** 1.73 ± 0.09** 0.91 ± 0.04** 0.15 ± 0.01
prazosin (0.03 mg/kg) 20.27 ± 2.33** 1.51 ± 0.14** 0.79 ± 0.09** 0.12 ± 0.01#
clonidine (0.15 mg/kg) 22.76 ± 1.88** 1.47 ± 0.07** 0.84 ± 0.05** 0.10 ± 0.01##
MPTP 3.38 ± 0.35 0.51 ± 0.05 0.44 ± 0.04 0.28 ± 0.01##
MPTP + mirtazapine (16 mg/kg) 1.90 ± 1.21 0.38 ± 0.08 0.29 ± 0.06 0.78 ± 0.25*
MPTP + mirtazapine (16 mg/kg) + WAY100635 (0.05 mg/kg) 2.25 ± 0.47 0.40 ± 0.10 0.32 ± 0.08 0.33 ± 0.05
MPTP + mirtazapine (16 mg/kg) + prazosin (0.03 mg/kg) 3.49 ± 0.48 0.56 ± 0.04 0.37 ± 0.01 0.28 ± 0.03
MPTP + mirtazapine (16 mg/kg) + clonidine (0.15 mg/kg) 2.90 ± 0.68 0.58 ± 0.68 0.45 ± 0.07 0.31 ± 0.04
  1. The results are shown as the mean (μg/g tissue) ± SEM of 4–6 animals/group. Statistical significance was evaluated by Student-Newman-Keuls test (F(DA) 8,40 = 84.267, F(DOPAC) 8,40 = 32.896, F(HVA) 8,40 = 29.578, F(Turnover) 8,40 = 4.232, *P < 0.05,**P < 0.01 compared with MPTP-treated group and P < 0.05 compared with MPTP + mirtazapine group), or by Student’s t-test (#P < 0.05, ##P < 0.01 compared with vehicle group).